Coastal Bridge Advisors LLC Cuts Stock Holdings in Zoetis Inc. $ZTS

Coastal Bridge Advisors LLC lowered its position in Zoetis Inc. (NYSE:ZTS) by 85.3% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 4,991 shares of the company’s stock after selling 28,875 shares during the period. Coastal Bridge Advisors LLC’s holdings in Zoetis were worth $730,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Savvy Advisors Inc. lifted its holdings in shares of Zoetis by 54.0% during the 2nd quarter. Savvy Advisors Inc. now owns 3,177 shares of the company’s stock worth $495,000 after acquiring an additional 1,114 shares during the last quarter. Sound Income Strategies LLC raised its position in Zoetis by 54.3% during the second quarter. Sound Income Strategies LLC now owns 432 shares of the company’s stock valued at $67,000 after purchasing an additional 152 shares in the last quarter. Chicago Partners Investment Group LLC boosted its holdings in shares of Zoetis by 67.0% in the 2nd quarter. Chicago Partners Investment Group LLC now owns 4,886 shares of the company’s stock worth $750,000 after purchasing an additional 1,961 shares in the last quarter. QRG Capital Management Inc. increased its position in shares of Zoetis by 4.9% during the 2nd quarter. QRG Capital Management Inc. now owns 77,741 shares of the company’s stock valued at $12,124,000 after purchasing an additional 3,616 shares during the last quarter. Finally, Consolidated Investment Group LLC raised its holdings in shares of Zoetis by 59.6% during the 2nd quarter. Consolidated Investment Group LLC now owns 26,235 shares of the company’s stock valued at $4,091,000 after buying an additional 9,800 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Trading Down 0.2%

NYSE:ZTS opened at $121.63 on Friday. The firm has a market capitalization of $53.60 billion, a P/E ratio of 20.48, a P/E/G ratio of 2.11 and a beta of 0.97. The company has a quick ratio of 2.28, a current ratio of 3.64 and a debt-to-equity ratio of 1.31. The company has a fifty day moving average of $124.03 and a 200 day moving average of $137.47. Zoetis Inc. has a 52 week low of $115.25 and a 52 week high of $177.40.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.62 by $0.08. The firm had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.42 billion. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The company’s quarterly revenue was up .5% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 3rd. Shareholders of record on Tuesday, January 20th will be issued a $0.53 dividend. This is an increase from Zoetis’s previous quarterly dividend of $0.50. The ex-dividend date is Tuesday, January 20th. This represents a $2.12 annualized dividend and a yield of 1.7%. Zoetis’s dividend payout ratio (DPR) is 35.69%.

Analyst Ratings Changes

A number of research analysts have commented on ZTS shares. UBS Group set a $136.00 price target on shares of Zoetis in a research report on Thursday. Wall Street Zen raised shares of Zoetis from a “hold” rating to a “buy” rating in a report on Friday, January 23rd. The Goldman Sachs Group upgraded shares of Zoetis to a “buy” rating in a research report on Monday, December 15th. KeyCorp started coverage on shares of Zoetis in a research note on Thursday, November 20th. They issued a “sector weight” rating for the company. Finally, Stifel Nicolaus reduced their price objective on Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a research note on Tuesday, November 18th. Five equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $152.45.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.